Icon

IRESSA (nda021399)- (250MG)

GEFITINIB ASTRAZENECA
250MG
No No
2017-May-05 Expired
None None
None No
IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA.
0 0 0
Total Other Developers 4
Drugs with Suitability No
250MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.